title: Silent celiac disease in patients with childhood localization-related epilepsies.
abstract: OBJECTIVE
  To evaluate how many patients with a clinical picture of idiopathic childhood localization-related epilepsies may also have silent celiac disease (CD). This will help determine whether investigation for CD should be restricted to those patients with childhood partial epilepsy with occipital paroxysms (CPEO) or should be extended to all patients with childhood partial epilepsy (CPE) regardless of seizure type and electroencephalographic (EEG) paroxysms.
  
  
  METHODS
  The study group consisted of 72 patients (31 girls and 41 boys; mean age, 12.6 +/- 4.28 years; age at onset, 6.4 +/- 3.7 years) who were observed consecutively over a 5-year period and who received an initial diagnosis of idiopathic CPE. A diagnosis of CD was confirmed by using enzyme-linked immunosorbent assay (ELISA) to assess the presence of antigliadin antibodies and the immunofluorescent undirected test to assess the presence of antiendomysium antibodies.
  
  
  RESULTS
  Twenty-five patients had CPEO, whereas the remaining 47 had CPE with centrotemporal spikes (CPEC). None of the patients with CPEC had positive antibody tests. Of the 25 patients with CPEO, two (8%) had antiendomysium immunoglobulin (Ig) A antibodies. In both of these patients, the jejunal biopsy showed atrophy of the villi and hyperplasia of the crypts, consistent with a diagnosis of CD. Brain computed tomography (CT) was normal in one of these patients and revealed occipital corticosubcortical calcifications in the other.
  
  
  CONCLUSIONS
  Our study indicates that CD screening should be performed routinely only in patients with CPEO.
authors.affiliation: Institute of Neurology, University Magna Graecia of Catanzaro, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Labate
authors.forename: A
authors.initials: A
authors.lastname: Gambardella
authors.forename: D
authors.initials: D
authors.lastname: Messina
authors.forename: S
authors.initials: S
authors.lastname: Tammaro
authors.forename: E
authors.initials: E
authors.lastname: Le Piane
authors.forename: D
authors.initials: D
authors.lastname: Pirritano
authors.forename: C
authors.initials: C
authors.lastname: Cosco
authors.forename: P
authors.initials: P
authors.lastname: Doldo
authors.forename: R
authors.initials: R
authors.lastname: Mazzei
authors.forename: R L
authors.initials: RL
authors.lastname: Oliveri
authors.forename: D
authors.initials: D
authors.lastname: Bosco
authors.forename: M
authors.initials: M
authors.lastname: Zappia
authors.forename: P
authors.initials: P
authors.lastname: Valentino
authors.forename: U
authors.initials: U
authors.lastname: Aguglia
authors.forename: A
authors.initials: A
authors.lastname: Quattrone
mesh_terms: D000367:Age Factors; D000906:Antibodies / Q000032:analysis; D002446:Celiac Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology; D002648:Child; D015897:Comorbidity; D004569:Electroencephalography / Q000706:statistics & numerical data; D004797:Enzyme-Linked Immunosorbent Assay; D004828:Epilepsies, Partial / Q000175:diagnosis / Q000453:epidemiology*; D019305:Epilepsy, Rolandic / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D005455:Fluorescent Antibody Technique; D005903:Gliadin / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007583:Jejunum / Q000473:pathology; D008297:Male
chemical_list: D000906:Antibodies; D007070:Immunoglobulin A; D005903:Gliadin